ArticleClinical ophthalmology (Auckland, N.Z.)2017
Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life.
Article in Clinical ophthalmology (Auckland, N.Z.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 2 syntheses or guidelines pooled it, 159 citations in OpenAlex.
- Association between central serous chorioretinopathy and personality types: A systematic review and meta-analysis.Acta ophthalmologica · 2026Pooled it
- Seasonal variation in the incidence of central serous chorioretinopathy: A systematic review and meta-analysis.Acta ophthalmologica · 2026Pooled it
- Long-term follow-up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half-dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4.Acta ophthalmologica · 2026Trial
- Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Trial
- Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data.Acta ophthalmologica · 2022Trial
- Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser.Acta ophthalmologica · 2021Trial
- Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.BMC ophthalmology · 2021Trial
- Characterizing the Natural History of Visual Function in Choroideremia Using Microperimetry and Multimodal Retinal Imaging.Investigative ophthalmology & visual science · 2017Trial
- Persistent fluid, persistent risk: predicting pachychoroid macular atrophy in chronic central serous chorioretinopathy.Eye (London, England) · 2026Article
- Risk factors for the development of subretinal fluid in the fellow eyes of patients with chronic central serous chorioretinopathy.Acta ophthalmologica · 2026Article
- Structure-Function Correlation in Patients With Central Serous Chorioretinopathy During Initial Disease Activity and After Ten Years.Investigative ophthalmology & visual science · 2026Article
- Utility of artificial intelligence for the diagnosis, prognosis, and management of central serous chorioretinopathy: a narrative review.International journal of retina and vitreous · 2026Review
- Effects of Selective Retina Therapy on Central Serous Chorioretinopathy with Serous Pigment Epithelial Detachments.Journal of clinical medicine · 2026Article
- Choroidal vascular hyperpermeability patterns in central serous chorioretinopathy correlate with microperimetry: CERTAIN study report 4.Acta ophthalmologica · 2026Article
- Long-term clinical outcomes and prognostic factors of central serous chorioretinopathy.BMC ophthalmology · 2026Article
- Quality of Life in Patients with Posterior Segment Eye Diseases.Journal of ophthalmic & vision research · 2026Review
- [Long-term outcome after photodynamic therapy of persistent central serous chorioretinopathy].Die Ophthalmologie · 2025Article
- Prevalence of central serous chorioretinopathy in Denmark.Acta ophthalmologica · 2025Article
- Effectiveness and safety of repeated photodynamic therapy in recurrent central serous chorioretinopathy.Acta ophthalmologica · 2025Article
- Outcome and safety of multiple photodynamic therapy sessions in chronic central serous chorioretinopathy.Acta ophthalmologica · 2025Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe the clinical findings and long-term outcome of patients with chronic central serous chorioretinopathy (cCSC). MATERIALS AND
methodsThis was a retrospective case series in 52 eyes of 36 patients with a follow-up period of at least 1 year. Extensive ophthalmic examination and a validated questionnaire concerning vision-related quality of life (National Eye Institute Visual Function Questionnaire [NEI-VFQ]-39) were analyzed.
resultsMean visual acuity showed a significant decline over time of 0.16 logarithm of minimum angle of resolution ([logMAR] range: -0.22 to 1.3;
conclusionThis study indicates that cCSC is a progressive disease in many patients, causing a progressive decline in visual acuity, accompanied by lower reported vision-related quality of life. In deciding whether or not to treat, the progressive nature of cCSC should be taken into account in this relatively young and often still professionally active patient group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.